275 related articles for article (PubMed ID: 9263357)
1. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
2. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
3. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
4. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
5. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.
Petrides PE; Siegel F
Blood Cells Mol Dis; 2006; 36(3):379-84. PubMed ID: 16563815
[TBL] [Abstract][Full Text] [Related]
6. [Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes].
Brière J; Kiladjian JJ; Peynaud-Debayle E
C R Seances Soc Biol Fil; 1996; 190(5-6):533-9. PubMed ID: 9074718
[TBL] [Abstract][Full Text] [Related]
7. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
8. Aspirin in essential thrombocythemia: status quo and quo vadis.
Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ
Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
[TBL] [Abstract][Full Text] [Related]
9. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Wehmeier A; Daum I; Jamin H; Schneider W
Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
[TBL] [Abstract][Full Text] [Related]
10. [Blood platelet changes in myeloproliferative disorders].
D'Angelo G; Calvano D; Giardini C
Minerva Med; 1988 Oct; 79(10):853-7. PubMed ID: 3141845
[TBL] [Abstract][Full Text] [Related]
11. [Platelet defects in chronic myeloproliferative disorders].
Raszeja-Specht A; Skibowska A; Kabata J; Hellmann A
Acta Haematol Pol; 1994; 25(3):253-60. PubMed ID: 7992598
[TBL] [Abstract][Full Text] [Related]
12. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
Murphy S; Davis JL; Walsh PN; Gardner FH
Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
[TBL] [Abstract][Full Text] [Related]
13. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease.
Wehmeier A; Scharf RE; Fricke S; Schneider W
Haemostasis; 1989; 19(5):251-9. PubMed ID: 2777137
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders.
Pareti FI; Gugliotta L; Mannucci L; Guarini A; Mannucci PM
Thromb Haemost; 1982 Apr; 47(2):84-9. PubMed ID: 7101243
[TBL] [Abstract][Full Text] [Related]
15. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
16. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
17. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
18. Platelet abnormalities in myeloproliferative disorders.
Holme S; Murphy S
Clin Lab Med; 1990 Dec; 10(4):873-88. PubMed ID: 2272179
[TBL] [Abstract][Full Text] [Related]
19. Blood cells diseases and thrombosis.
Leone G; Sica S; Chiusolo P; Teofili L; De Stefano V
Haematologica; 2001 Dec; 86(12):1236-44. PubMed ID: 11726314
[TBL] [Abstract][Full Text] [Related]
20. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
